Department of Urology, Santa Chiara Hospital, Trento, Italy.
Department of Urology, University of Florence, Florence, Italy.
Future Microbiol. 2019 Aug;14:1013-1021. doi: 10.2217/fmb-2019-0145.
To evaluate the efficacy of a medical device containing xyloglucan, hibiscus and propolis in the management of recurrent urinary tract infections (rUTIs). Sixty-one women affected by rUTIs received this medical device, one capsule a day for 15 days (one cycle every month, for 6 months), in an observational, prospective study. Clinical and microbiological evaluations were performed at baseline and 1, 3 and 6 months from enrolment. At first follow-up, 41 reported a clinical improvement and a return to their clinical status before UTI, while 47 and 51 did so at the second and third follow-up evaluations. A statistically significant clinical improvement was reported at each follow-up visit (quality of life [QoL] 94.2 vs 98.6; QoL 94.1 vs 98.7; QoL 94.2 vs 99.1; p < 0.001). A statistically significant reduction in antibiotic use was reported. This medical device is able to improve quality of life in women with rUTIs, reduce recurrences and antibiotic use.
评估含有木葡聚糖、芙蓉和蜂胶的医疗器械在管理复发性尿路感染（rUTIs）中的疗效。61 名 rUTIs 女性患者接受了这种医疗器械，每天一粒，持续 15 天（每月一个周期，持续 6 个月），这是一项观察性、前瞻性研究。在基线和入组后 1、3 和 6 个月进行临床和微生物学评估。最初的随访中，有 41 人报告了临床改善，并恢复到 UTI 前的临床状态，而在第二次和第三次随访中，有 47 人和 51 人报告了同样的情况。在每次随访时都报告了统计学上显著的临床改善（生活质量[QoL]94.2 对 98.6；QoL 94.1 对 98.7；QoL 94.2 对 99.1；p<0.001）。报告显示抗生素使用量显著减少。这种医疗器械能够提高 rUTIs 女性的生活质量，减少复发和抗生素的使用。
